Emerging novel therapeutics in triple-negative breast cancer Journal Article
| Authors: | Lyons, T. G.; Traina, T. A. |
| Article Title: | Emerging novel therapeutics in triple-negative breast cancer |
| Abstract: | The mortality from breast cancer has steadily decreased due in part to early detection and advances in therapy. The treatment options for breast cancer vary considerably depending on the histological subtype. There are a number of very effective targeted therapies available for estrogen receptor-positive disease and for human epidermal growth factor receptor 2-positive disease. However, triple-negative breast cancer is a particularly aggressive subtype. This subtype represents an unmet need for improved therapies. TNBC is a heterogenous subtype of breast cancer that is beginning to be refined by its molecular characteristics and clinical response to a targeted therapeutic approach. Here we review the recent advances in the treatment of TNBC with emphasis on the many emerging novel targeted therapies. © 2019, Springer Nature Switzerland AG. |
| Keywords: | androgen receptor; targeted therapies; molecularly targeted therapy; triple negative breast cancer; triple-negative breast cancer; molecular targeted therapy; parp inhibitor; antibody-drug conjugate; humans; human; female; checkpoint inhibitor; akt inhibitor; triple negative breast neoplasms |
| Journal Title: | Advances in Experimental Medicine and Biology |
| Volume: | 1152 |
| ISSN: | 0065-2598 |
| Publisher: | Springer |
| Date Published: | 2019-01-01 |
| Start Page: | 377 |
| End Page: | 399 |
| Language: | English |
| DOI: | 10.1007/978-3-030-20301-6_20 |
| PUBMED: | 31456195 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Chapter 20 in "Breast Cancer Metastasis and Drug Resistance: Challenges and Progress" (ISBN: 978-3-030-20300-9) -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work